Infections due to nontuberculous mycobacteria;Infekcije izazvane netuberkuloznim mikobakterijama

Lijecnicki Vjesnik

Volumn 129, Issue 5, 2007, Pages 146-151

  Katalinić Janković, Vera ^a,e   Grle, Sanja Popović ^b   Obrovac, Mihaela ^a   Cvetnic, Zeljko ^c   Alfirević, Taida ^d  

^a Hrvatski Zavod za Javno Zdravstvo ^*  (Croatia)

^b Klinika za Plucne Bolesti Jordanovac   (Croatia)

^c CROATIAN VETERINARY INSTITUTE   (Croatia)

^d Specijalna bolnica za plu ne bolesti   (Croatia)

^e CROATIAN NATIONAL INSTITUTE OF PUBLIC HEALTH   (Croatia)

Author keywords

Drug effects; anti bacterial agents; Microbiology, diagnosis, drug therapy; mycobacteria, atypical; Mycobacterium infections, atypical; Therapeutic use

Indexed keywords

ARTICLE; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY;

HUMANS; MYCOBACTERIA, ATYPICAL; MYCOBACTERIUM INFECTIONS, ATYPICAL;

EID: 34547153721     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Schloosberg D. Tuberculosis and nontuberculous mycobacterial infections, 4. izd. Philadelphia; W.B. Saunders Company: 1999.
2. Wolinsky E. Mycobacterial diseases other than tuberculosis. Clin Infect Dis 1992;15:1-12.
3. Martin-Casabona N, Bahrmand AR, Bennedsen J i sur. Spanish group for non-tuberculous mycobacteria. Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis 2004;10:1186-93.
4. Timpe A, Runyon EH. The relationship of »atypical« acid-fast bacteria to human disease - a preliminary report. J Lab Clin Med 1954;44: 202-9.
5. Runyon EH. Anonymous mycobacteria in pulmonary disease. Med Clin North Am 1959;43:273-90.
6. Davidson PT. The diagnosis and management of disease caused by M. avium complex, M. kansasii, and other mycobacteria. Clin Chest Med 1989;10:431-43.
7. Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 2003;16:319-54.
8. Brown-Elliot BA, Wallace RJ. Clinical and taxonomic status of patogenic nonpigmented or late-pigmented rapidly growing mycobacteria. Clin Microbiol Rev 2002;15:716-46.
9. Kennedy TP, Weber DJ. Nontuberculous mycobacteria an underappreciated cause of geriatric lung disease. Am J Crit Care Med 1994;149:1654-8.
10. Falkinham JO III. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 1996;9:177-215.
11. Debrunner M, Salfinger M, Brandli O, von Graevenitz A. Epidemiology and clinical significance of nontuberculous mycobacteria in patients negative for human immunodeficiency virus in Switzerland. Clin Infect Dis 1992;15:330-45.
12. Tsukamura M, Kita N, Shimoide H, Arakawa H, Kuze A. Studies on the epidemiology of nontuberculous mycobacteria in Japan. Am Rev Respir Dis 1988;137:1280-4.
13. Falkinham JO III. Natural ecology and survival in water of mycobacteria of potential public health significance. U: Pedley S, Bartram J, Rees G, Dufour A, Cotruvo JA, ur. Pathogenic mycobacteria in water: a guide to public health consequences, monitoring and management. Geneve: World Health Organization publication; 2004., str. 15-26.
14. Cantanzaro A. Diagnosis, differentiating colonization, infection, and disease. Clin Chest Med 2002;23:599-601.
15. American Thoracic Society. Diagnostic and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156:S1-S25
16. British Thoracic Society. Management of opportunist mycobacterial infections: Joint tuberculosis committee guidelines 1999. Thorax 2000; 55:210-8.
17. Yamamoto M, Ogura Y, Sudo K, Hibino S. Diagnostic criteria for disease caused by atypical mycobacteria. Am Rev Respir Dis 1967;96: 773-8.
18. Heifets L. Mycobacterial infections caused by nontuberculous mycobacteria. Semin Respir Crit Care Med 2004;25:283-95.
19. Tortoli E. Clinical features of infections caused by new nontuberculous mycobacteria. Part I. Clin Microbiol Newsletter 2004;26:86-96.
20. Tortoli E. Clinical features of infections caused by new nontuberculous mycobacteria. Part II. Clin Microbiol Newsletter 2004;26:97-100.
21. Primm TP, Lucero CA, Falkinham JO III. Health impacts of environmental mycobacteria. Clin Microbiol Rev 2004;17:98-106.
22. Patz EF, Swensen SJ, Erasmus J. Pulmonary manifestations of nontuberculous mycobacterium. Radiol Clin North Am 1995;33:719-735.
23. von Reyn CF, Maslow JN, Barber TW. Persistent colonisation of potable water as a source of Mycobacterium avium infection in AIDS. Lancet 1994;343(8906):1137-41.
24. Miller WT Jr. Spectrum of pulmonary nontuberculous mycobacterial infection. Radiology 1994;191:343-50.
25. Suomalainen S, Koukila-Kahkola P, Brander E, Katila ME, Piilonen A, Paulin L, Mattons K. Pulmonary infection caused by an unusual, slowly growing nontuberculous mycobacterium. J Clin Microbiol 2001;39:2668-71.
26. Faress JA, McKinney LA, Semaan MT, Byrd RP, Mehta JB, Roy TM. Mycobacterium xenopi Pneumonia in the Southeastern United States. South Med J 2003;96:596-9.
27. Falkinham JO III. Mycobacterial aerosols and respiratory disease. Emerg Infect Dis 2003;9:763-7.
28. Nenry MT, Inamdar L, O'Riordain D, Schweiger M, Watson JP. Non-tuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response. Eur Respir J 2004;23:741-6.
29. Ormerod P. A step forward in the evidence-based treatment of opportunist mycobacteria. Thorax 2001;56:163.
30. Heginbothom ML. The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment. Int J Tuberc Lung Dis 2001;5:539-45.
31. Piersimoni C, Zitti PG, Nista D, Borginia S. Mycobacterium celatum pulmonary infection in the immunocompetent: case report and review. Emerg Infect Dis 2003;9:1-6.
32. Won-Jung K, Jung Kwon O, Kyung Soo Lee. Nontuberculous mycobacterial pulmonary diseases in immunocompetent patients. Korean J Radiol 2002;3:145-57.
33. Research Committee of the British Thoracic Society. First randomised trial of treatment for pulmonary disease caused by M. avium intracellulare, M. malmoense, and M. xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001;56:167-72.
34. Chaisson RE, Benson CA, Dube MP. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS clinical trials group protocol 157 study team. Ann Intern Med 1994;121(12):905-11.
35. Research Committee of the British Thoracic Society. Pulmonary diseases caused by M. malmoense in HIV negative patients: 5-yr follow up of patients receiving standardized treatment. Eur Respir J 2003;21:478-82.
36. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 1992;101(6):1605-9.
37. Pauls RJ, Turenne CY, Wolfe N, Kabani A. A high proportion of novel mycobacteria species identified by 16S rRNA analysis among slowly growing accuProbe-negative strains in a clinical setting. Am J Clin Pathol 2003;120:560-6.